World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT01640496
Date of registration: 11/07/2012
Prospective Registration: No
Primary sponsor: University of Chicago
Public title: Vitamin D Treatment in Ulcerative Colitis Vitamin D
Scientific title: Vitamin D Treatment in Ulcerative Colitis
Date of first enrolment: July 2012
Target sample size: 0
Recruitment status: Withdrawn
URL:  http://clinicaltrials.gov/show/NCT01640496
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Phase:  N/A
Countries of recruitment
United States
Contacts
Name:     Joel Pekow, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Chicago
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients must be over 18 years of age

- have a diagnosis of UC as confirmed by histology.

- UC patients must have active but mild disease as confirmed by a Mayo Clinic endoscopy
score from 2-4,

- not requiring medication adjustment during the trial.

- Patients must be capable of understanding the purpose, risks and expectations of
study participation and willing to provide written informed consent.

Exclusion Criteria:

- Individuals on vitamin D or laxative therapy (except for purposes of endoscopy
preparation),

- UC patients with fulminant colitis or active C difficile or other colonic infections,

- age<18 year old,

- individuals with bleeding disorders will be excluded from the study.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Inflammatory Bowel Disease
Ulcerative Colitis
Intervention(s)
Other: Placebo
Drug: Vitamin D3
Primary Outcome(s)
Mucosal Permeability [Time Frame: 8 weeks]
Secondary Outcome(s)
Mucosal tight junction protein expression [Time Frame: 8 weeks]
Secondary ID(s)
11-0542
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
North Shore University Hospital
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history